Elson PJ - Search Results

1

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC. Weng DE, et al. Among authors: elson pj. Mol Cancer Ther. 2005 Jun;4(6):948-55. doi: 10.1158/1535-7163.MCT-04-0210. Mol Cancer Ther. 2005. PMID: 15956252 Clinical Trial.

2

High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.

Trump DL, Elson PJ, Borden EC, Harris JE, Tuttle RL, Whisnant JK, Oken MM, Carignan JR, Ruckdeschel JC, Davis TE. Trump DL, et al. Among authors: elson pj. Cancer Treat Rep. 1987 Feb;71(2):165-9. Cancer Treat Rep. 1987. PMID: 3802113

3

Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.

Bukowski RM, Olencki T, Gunn H, McLain D, Budd GT, Sandstrom K, Tuason L, Redovan C, Rayman P, Tubbs R, Resta D, Elson P, Finke J. Bukowski RM, et al. Clin Cancer Res. 1996 Feb;2(2):347-57. Clin Cancer Res. 1996. PMID: 9816178 Clinical Trial.

4

Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.

van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT. van Stolk R, et al. Clin Cancer Res. 2000 Jan;6(1):78-89. Clin Cancer Res. 2000. PMID: 10656435 Clinical Trial.

5

Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects.

Olencki T, Finke J, Tubbs R, Elson P, McLain D, Herzog P, Budd GT, Gunn H, Bukowski RM. Olencki T, et al. J Immunother. 2000 Sep-Oct;23(5):549-56. doi: 10.1097/00002371-200009000-00005. J Immunother. 2000. PMID: 11001548 Clinical Trial.

6

GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial.

Hussein MA, Sandstrom K, Elson P, Finke J, McLain D, Rayman P, Rybicki LA, Bukowski RA. Hussein MA, et al. J Cancer Res Clin Oncol. 2001 Oct;127(10):619-24. doi: 10.1007/s004320100250. J Cancer Res Clin Oncol. 2001. PMID: 11599798

7

Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.

He XY, Elson P, Pohlman B, Lichtin A, Hussein M, Andresen S, Kalaycio M. He XY, et al. BMC Cancer. 2002 May 9;2:12. doi: 10.1186/1471-2407-2-12. BMC Cancer. 2002. PMID: 12019034 Free PMC article. Clinical Trial.

8

Telomerase activity in stage II colorectal carcinoma.

Kawanishi-Tabata R, Lopez F, Fratantonio S, Kim N, Goldblum J, Tubbs R, Elson P, Lavery I, Bukowski RM, Ganapathi R, Ganapathi MK. Kawanishi-Tabata R, et al. Cancer. 2002 Nov 1;95(9):1834-9. doi: 10.1002/cncr.10911. Cancer. 2002. PMID: 12404275 Free article.

9

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.

Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM. Hussein MA, et al. Cancer. 2002 Nov 15;95(10):2160-8. doi: 10.1002/cncr.10946. Cancer. 2002. PMID: 12412170 Free article. Clinical Trial.

10

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.

Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, Peereboom D, Pelley R, Bukowski RM. Mekhail T, et al. Cancer. 2003 Jan 1;97(1):170-8. doi: 10.1002/cncr.10991. Cancer. 2003. PMID: 12491518 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page